Heart disease in dogs is almost as common as it is in humans,affecting approximately 10 percent of dogs in their lifetime1

Previous studies have shown thatVETMEDIN®could helpimprovethesurvivaltimeand qualityoflifefordogswithcongestiveheartfailureduetomyxomatousmitralvalvedisease (MMVD) or dilated cardiomyopathy (DCM)2,3

The newVETMEDIN®Solutionofferspetownersaconvenient,liquidoraltreatmentoptionfor those dogs that prefer a liquid

DULUTH,Ga,Nov. 23,2024 -- Boehringer Ingelheim,aglobal leaderinanimal health,launchedVETMEDIN®Solution,the firstoralsolution approvedby theU.S.Food and Drug Administration(FDA) forthemanagementof congestiveheartfailure(CHF)in dogsdue to MMVD or DCM.

Unfortunately,heart disease in dogs is common,affecting approximately 10 percent of dogs in their lifetime.1 Most frequently,dogs are affected by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM),both which may progress to CHF,characterized by the inability of the heart to effectively pump blood throughout the body.

Nowpetownershaveaconvenient,newmanagementoptiontosupporttheheartsofdogswith CHF:aliquidversion ofVETMEDIN®,oneoftheleadingcanine cardiologymedicationsintheworld. Previous studies have shown that VETMEDIN® could help increase the survival time and quality of lifeindogsduetoMMVDorDCM.2,3

IMPORTANT SAFETYINFORMATION: VETMEDIN®Solution (pimobendan oral solution) andVETMEDIN®(pimobendan)ChewableTablets

VETMEDIN® Solution (pimobendan oral solution) and VETMEDIN® (pimobendan) Chewable Tablets areforusein dogswith clinicalevidenceofheartfailureonlyandshouldnotbegiven in case of hypertrophic cardiomyopathy,aortic stenosis,or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information,seefullprescribinginformationforVetmedinSolutionorseefullprescribinginformationforVetmedin ChewableTabletsorvisitVetmedinclinic.com

"We continue todelivernewinnovations rootedinrobustclinicalevidence to helpmorepets,"said DanielWatkins,VPUSPetBusiness,BoehringerIngelheim."Weknowsomedogsandpetowners maypreferaliquidmedication,especiallyforsmaller dogs.WithVETMEDIN®Solution,aneasy-to- use liquid formulation,we can help more dogs with heart disease have longer survival and live better lives."

VETMEDIN®Solution,nowavailableintheU.S.,providesthesamedualmodeofactionas VETMEDIN® Chewable Tablets. The flavorless,twice-daily liquid oral solution should be administered directly into the dog's mouth.

SinceVETMEDIN®wasfirstintroduced25yearsago,dogsandtheirownersaroundtheworldhave enjoyed more than 1 million years of additional life to love.4 VETMEDIN®Chewable Tablets are approvedforthemanagementofthesignsofmild,moderate,orsevere CHFindogsduetoclinical MMVD or DCM. VETMEDIN® Chewable Tablets are indicated for use with concurrent therapy for congestive heart failure (e.g.,furosemide,etc.) as appropriate on a case-by-case basis.

Boehringer Ingelheim also offers VETMEDIN®-CA1 (pimobendan),which has FDA conditional approvalforuseindogswithStageB2preclinicalMMVD–whichmayenableadelayintheonset of heart failure symptoms.

Formoreinformation,visitwww.boehringer-ingelheim.com/animal-health.

IMPORTANT SAFETYINFORMATION: VETMEDIN®Solution (pimobendan oral solution) andVETMEDIN®(pimobendan)ChewableTablets

VETMEDIN®SolutionandVETMEDIN®Chewable Tabletsareforuseindogswithclinicalevidence of heart failure only. The most common side effects reported in field studies were poor appetite,lethargy,diarrhea,dyspnea,azotemia,weakness,andataxia.VETMEDIN®SolutionandVETMEDIN® Chewable Tablets should not be given in case of hypertrophic cardiomyopathy,or anyotherclinicalconditionwhereanaugmentationofcardiacoutputisinappropriatefor functional or anatomical reasons. For more information,see full prescribing information

orvisitVetmedinclinic.com

IMPORTANTSAFETYINFORMATION:VETMEDIN®-CA1(pimobendan)

VETMEDIN®-CA1(pimobendan)isfor useonlyindogswithpreclinicalMMVDthathavea moderateor loudmitralmurmurdue tomitralregurgitationand cardiomegaly(StageB2MMVD,2019ACVIMConsensusStatement1).Is aviolationofFederallawto usethisproductotherthan asdirectedinthe labeling.VETMEDIN-CA1isconditionallyapprovedby FDApendingafull demonstrationofeffectivenessunderapplicationnumber141-556.Formoreinformation,seefullprescribing informationor visit Vetmedinclinic.com

AboutBoehringer Ingelheim

BoehringerIngelheim isabiopharmaceuticalcompanyactive inbothhuman andanimalhealth. As one of the industry's top investors in Research and Development,the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885,Boehringer takes a long-term perspective,embedding sustainability along the entirevalue chain. Morethan53,500 employeesserveover130marketstobuild ahealthier,more sustainable,and equitable tomorrow. Lean more at boehringer-ingelheim.com/us.

AboutBoehringer Ingelheim–AnimalHealthbusiness

Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines,parasite-control products,and medicines for pets,horses,and livestock to veterinarians,animal owners,farmers,and governments. As a leader in animal health,Boehringer Ingelheim values that the health of humans and animals is deeplyconnectedandstrivestomakeadifferenceforpeople,animals,andsociety.Learnmoreat boehringer-ingelheim.com/animal-health.

MediaContact:

Chrissy Jones

Director,Corporate Affairs Boehringer Ingelheim

christine.jones@boehringer.com

References

1Keene,Bruce W et al. "ACVIM consensus guidelines for the diagnosis and treatment of myxomatousmitralvalvedisease indogs."JournalofVeterinaryInternal Medicinevol.33,3(2019): 1127-1140. doi:10.1111/jvim.15488

2 Häggström,Jetal."Longitudinalanalysisofqualityoflife,clinical,radiographic,echocardiographic,and laboratory variables in dogs with myxomatous mitral valve disease receivingpimobendanorbenazepril:theQUESTstudy."JournalofVeterinaryInternalMedicinevol. 27,6(2013):1441-51. doi:10.1111/jvim.12181

3Lombard,ChristopheWetal."Clinicalefficacyof pimobendanversusbenazeprilforthetreatment of acquired atrioventricular valvular disease in dogs." Journal of the American Animal Hospital Association vol. 42,4 (2006): 249-61. doi:10.5326/0420249

4Epidemiologic simulation of Vetmedin usage 1999-2024,based on EPIC 2016 JVIM (MMVD,stage B2),QUEST 2008JVIM(MMVD,stageC),PROTECT 2012JVIM(DCM,stageB2),O`Grady2008JVIM

(DCM,Fuentes 2002JVIM(DCMstageC)andBI-owned salesdata.

VETMEDIN®isaregisteredtrademarkofBoehringerIngelheimVetmedicaGmbH,used under license. ©2024 BoehringerIngelheimAnimalHealthUSAInc.,Duluth,GA.Allrights reserved.